Drug-Device Combination Products: Where do they fall within the new MDR Regime?
Continuing our series of publications, in this briefing we examine the key changes to the regulatory pathway for drug-device combination products (DDCs) in advance of the Medical Devices Regulation (MDR) becoming fully applicable in May 2021.

 

With innovation leading to the increasing integration of drugs and devices, traditional boundaries between medicines and medical devices are often blurred. As a result, determining the correct regulatory pathway for drug-device combination products (DDCs) can prove challenging.

The development of these products involves interaction between EU and national regulations, one of which, the Medical Devices Regulation (MDR), is set to become fully applicable on 26 May 2021.

In this briefing we examine the key changes to the regulatory pathway for DDCs.

Click here or on the image below to download this briefing, or click the following links to view the rest of our series: 

Drug Devices